{"url_path":"/sec/kros/8-k/2026-06-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1664710/0001664710-26-000032-index.html","accession_number":"0001664710-26-000032","cik":"0001664710","ticker":"KROS","issuer_name":"Keros Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1664710/0001664710-26-000032-index.html","primary_entity_key":"0001664710","primary_entity_name":"Keros Therapeutics, Inc."},"word_count":81,"has_tables":true,"body_markdown":"Item 9.01     Financial Statements and Exhibits.\n\n \n\n(d) Exhibits\n\nExhibit  \n\nNo. Description\n\n[99.1](exhibit9916126pr.htm)\n \n[Press Release dated](exhibit9916126pr.htm)[June](exhibit9916126pr.htm)[1](exhibit9916126pr.htm)[, 2026.](exhibit9916126pr.htm)\n\n104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nKEROS THERAPEUTICS, INC.\n\nBy: /s/ Jasbir Seehra\n\n \nJasbir Seehra, Ph.D.\n\nChief Executive Officer\n\nDated: June 1, 2026"}